// App-Quantinova.ai

1421 : The Role of Her2/Neu in ALL: Long Term Clinical Follow-up of Surface-Positive Patients and Induction of NK Cell ADCC by Trastuzumab in Vitro

Researchers

Presenter

  • Benjamin J Schmiedel

Principal Investigators

  • Nora Roth

  • Christoph Faul

  • Robert Mohle

  • Marc Schmalzing

  • Lothar Kanz

  • Wichard Vogel

  • Helmut R Salih

Medical Centers

  • Abteilung fur Hamatologie, Onkologie, Immunologie, Rheumatologie und Pulmologie, Medizinische Universitatsklinik Tubingen, Tuebingen, Germany

  • Department of Internal Medicine II, University of Tuebingen, Tuebingen, Germany

  • Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany

  • Department of Dermatology Eberhard-Karls University of Tuebingen, Tuebingen, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Natural Killer cells

  • Breakpoint Cluster Region

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved